Immunovia AB
IMMVF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.73M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.73 Million |
|---|---|
| Enterprise Value | $-21,660,309.00 |
| Earnings per Share | $-0.42 |
| Beta | 2.65 |
| Outstanding Shares | 672,666,892 |
Return
| Return on Equity | -372.43% |
|---|---|
| Return on Assets | -183.25% |
| Return on Invested Capital | -251.03% |
Valuation & Multiples
| P/E Ratio | -0.3 |
|---|---|
| PEG | 0.67 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.4 |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 1.23 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.00
Consensus analyst estimateRevenue Estimate
$49,750
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.00
Consensus analyst estimateRevenue Estimate
$49,750
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Immunovia AB
13 employees
CEO: Jeff Borcherding
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indica...